S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
American Express profits jump 34%, helped by jump in new customers, higher spending
American Express, Fifth Third rise; Netflix, PPG Industries fall, Friday, 4/19/2024
Intuitive Surgical Stock Can Trend Much Higher This Year 
3 Magnificent Seven Stocks Outperforming the Rest
Bargain Hunting: 3 Stocks With RSIs That Scream Oversold
Closing prices for crude oil, gold and other commodities

Zoetis (ZTS) Competitors

$146.45
-6.66 (-4.35%)
(As of 04/19/2024 ET)

ZTS vs. BMY, PFE, GSK, TAK, REGN, VRTX, SNY, GMAB, ALNY, and ABT

Should you be buying Zoetis stock or one of its competitors? The main competitors of Zoetis include Bristol-Myers Squibb (BMY), Pfizer (PFE), GSK (GSK), Takeda Pharmaceutical (TAK), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Sanofi (SNY), Genmab A/S (GMAB), Alnylam Pharmaceuticals (ALNY), and Abbott Laboratories (ABT). These companies are all part of the "pharmaceutical preparations" industry.

Zoetis vs.

Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends, community ranking and analyst recommendations.

Bristol-Myers Squibb received 184 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.74% of users gave Zoetis an outperform vote while only 66.96% of users gave Bristol-Myers Squibb an outperform vote.

CompanyUnderperformOutperform
ZoetisOutperform Votes
894
77.74%
Underperform Votes
256
22.26%
Bristol-Myers SquibbOutperform Votes
1078
66.96%
Underperform Votes
532
33.04%

Zoetis pays an annual dividend of $1.73 per share and has a dividend yield of 1.2%. Bristol-Myers Squibb pays an annual dividend of $2.40 per share and has a dividend yield of 4.9%. Zoetis pays out 34.1% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 62.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$8.54B7.84$2.34B$5.0728.89
Bristol-Myers Squibb$45.01B2.20$8.03B$3.8612.68

Zoetis currently has a consensus price target of $221.75, suggesting a potential upside of 51.42%. Bristol-Myers Squibb has a consensus price target of $61.18, suggesting a potential upside of 25.03%. Given Zoetis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zoetis is more favorable than Bristol-Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis
0 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bristol-Myers Squibb
1 Sell rating(s)
15 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.11

Zoetis has a net margin of 27.43% compared to Bristol-Myers Squibb's net margin of 17.83%. Zoetis' return on equity of 51.25% beat Bristol-Myers Squibb's return on equity.

Company Net Margins Return on Equity Return on Assets
Zoetis27.43% 51.25% 17.58%
Bristol-Myers Squibb 17.83%50.95%16.67%

In the previous week, Bristol-Myers Squibb had 4 more articles in the media than Zoetis. MarketBeat recorded 38 mentions for Bristol-Myers Squibb and 34 mentions for Zoetis. Bristol-Myers Squibb's average media sentiment score of 0.46 beat Zoetis' score of 0.15 indicating that Bristol-Myers Squibb is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoetis
15 Very Positive mention(s)
5 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
3 Very Negative mention(s)
Neutral
Bristol-Myers Squibb
17 Very Positive mention(s)
2 Positive mention(s)
9 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral

92.8% of Zoetis shares are owned by institutional investors. Comparatively, 76.4% of Bristol-Myers Squibb shares are owned by institutional investors. 0.1% of Zoetis shares are owned by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Zoetis has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Summary

Zoetis beats Bristol-Myers Squibb on 14 of the 20 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ZTS vs. The Competition

MetricZoetisPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$66.98B$6.17B$4.82B$17.21B
Dividend Yield1.14%3.11%2.94%3.62%
P/E Ratio28.8917.53269.3924.83
Price / Sales7.84278.432,448.3511.92
Price / Cash23.6629.8947.2417.10
Price / Book13.475.434.554.85
Net Income$2.34B$134.01M$104.05M$970.56M
7 Day Performance-2.35%-6.65%-4.49%-1.75%
1 Month Performance-14.34%-9.61%-6.67%-3.82%
1 Year Performance-16.03%-5.42%7.73%100.03%

Zoetis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BMY
Bristol-Myers Squibb
4.8516 of 5 stars
$48.27
-0.5%
$61.12
+26.6%
-30.0%$97.83B$45.01B12.5134,100Upcoming Earnings
Analyst Report
Short Interest ↓
Analyst Revision
PFE
Pfizer
4.9869 of 5 stars
$25.69
-0.8%
$36.88
+43.5%
-35.4%$145.47B$58.50B71.3688,000
GSK
GSK
2.6689 of 5 stars
$39.95
-1.4%
N/A+7.6%$82.78B$37.71B13.2770,200
TAK
Takeda Pharmaceutical
0.2679 of 5 stars
$13.24
+0.5%
$14.00
+5.7%
-20.5%$41.90B$4.17T20.0649,095News Coverage
REGN
Regeneron Pharmaceuticals
3.6343 of 5 stars
$894.14
-0.5%
$970.57
+8.5%
+10.9%$98.14B$13.12B25.7313,450Analyst Report
Gap Up
VRTX
Vertex Pharmaceuticals
4.3302 of 5 stars
$394.17
-0.8%
$424.62
+7.7%
+20.0%$101.88B$9.87B28.385,400Analyst Report
Analyst Revision
News Coverage
SNY
Sanofi
3.0726 of 5 stars
$45.80
-1.0%
$55.00
+20.1%
-16.9%$115.86B$46.61B19.4186,088Upcoming Earnings
Analyst Revision
News Coverage
GMAB
Genmab A/S
3.9456 of 5 stars
$29.43
-0.3%
$48.50
+64.8%
-29.2%$19.46B$2.39B30.662,204Analyst Revision
ALNY
Alnylam Pharmaceuticals
4.2843 of 5 stars
$146.72
-0.7%
$216.12
+47.3%
-28.6%$18.48B$1.83B-41.212,100
ABT
Abbott Laboratories
4.9951 of 5 stars
$109.20
+0.3%
$122.14
+11.9%
-4.5%$189.48B$40.11B33.50114,000Earnings Report
Analyst Report

Related Companies and Tools

This page (NYSE:ZTS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners